A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).
Clinical trial NCT06105619 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06105619
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-08
- Primary completion
- 2023-04-01
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.